|
1
|
Cutaneous squamous cell carcinoma arising in immunosuppressed patients: a systematic review of tumor profiling studies. JID INNOVATIONS 2022; 2:100126. [PMID: 35620703 PMCID: PMC9127418 DOI: 10.1016/j.xjidi.2022.100126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2021] [Revised: 02/08/2022] [Accepted: 03/04/2022] [Indexed: 12/01/2022] Open
Abstract
As solid organ transplantation becomes more prevalent, more individuals are living as members of the immunosuppressed population with an elevated risk for cutaneous squamous cell carcinoma (cSCC). Although great progress has been made in understanding the pathogenesis of cSCC in general, little is known about the drivers of tumorigenesis in immunosuppressed patients and organ-transplant recipients, specifically. This systematic review sought to synthesize information regarding the genetic and epigenetic alterations as well as changes in protein and mRNA expression that place this growing population at risk for cSCC, influence treatment response, and promote tumor aggressiveness. This review will provide investigators with a framework to identify future areas of investigation and clinicians with additional insight into how to best manage these patients.
Collapse
|
|
2
|
Li Q, Ma C, Zhang Z, Chen S, Zhi W, Zhang L, Zhang G, Shi L, Cao F, Ma T. Association between cyclooxygenase-2 (COX-2) 8473 T > C polymorphism and cancer risk: a meta-analysis and trial sequential analysis. BMC Cancer 2018; 18:847. [PMID: 30143023 PMCID: PMC6109290 DOI: 10.1186/s12885-018-4753-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2018] [Accepted: 08/14/2018] [Indexed: 12/23/2022] Open
Abstract
Background Numerous studies have investigated the relationship between COX-2 8473 T > C polymorphism and cancer susceptibility, however, the results remain controversial. Therefore, we carried out the present meta-analysis to obtain a more accurate assessment of this potential association. Methods In this meta-analysis, 79 case-control studies were included with a total of 38,634 cases and 55,206 controls. We searched all relevant articles published in PubMed, EMBASE, OVID, Web of Science, CNKI and Wanfang Data, till September 29, 2017. The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the strength of the association. We performed subgroup analysis according to ethnicity, source of controls, genotyping method and cancer type. Moreover, Trial sequential analysis (TSA) was implemented to decrease the risk of type I error and estimate whether the current evidence of the results was sufficient and conclusive. Results Overall, our results indicated that 8473 T > C polymorphism was not associated with cancer susceptibility. However, stratified analysis showed that the polymorphism was associated with a statistically significant decreased risk for nasopharyngeal cancer and bladder cancer, but an increased risk for esophageal cancer and skin cancer. Interestingly, TSA demonstrated that the evidence of the result was sufficient in this study. Conclusion No significant association between COX-2 8473 T > C polymorphism and cancer risk was detected. Electronic supplementary material The online version of this article (10.1186/s12885-018-4753-3) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Qiuping Li
- Department of Medical Oncology, Luohe Central Hospital, Luohe First People's Hospital, No. 56 People's East Road, Luohe City, 462000, Henan Province, China
| | - Chao Ma
- Department of Medical Oncology, Luohe Central Hospital, Luohe First People's Hospital, No. 56 People's East Road, Luohe City, 462000, Henan Province, China
| | - Zhihui Zhang
- Department of Medical Oncology, Luohe Central Hospital, Luohe First People's Hospital, No. 56 People's East Road, Luohe City, 462000, Henan Province, China
| | - Suhua Chen
- Department of Medical Oncology, Luohe Central Hospital, Luohe First People's Hospital, No. 56 People's East Road, Luohe City, 462000, Henan Province, China
| | - Weiguo Zhi
- Department of Medical Oncology, Luohe Central Hospital, Luohe First People's Hospital, No. 56 People's East Road, Luohe City, 462000, Henan Province, China
| | - Lei Zhang
- Department of Medical Oncology, Luohe Central Hospital, Luohe First People's Hospital, No. 56 People's East Road, Luohe City, 462000, Henan Province, China
| | - Guoyao Zhang
- Department of Medical Oncology, Luohe Central Hospital, Luohe First People's Hospital, No. 56 People's East Road, Luohe City, 462000, Henan Province, China
| | - Lei Shi
- Department of Medical Oncology, Luohe Central Hospital, Luohe First People's Hospital, No. 56 People's East Road, Luohe City, 462000, Henan Province, China
| | - Fei Cao
- Department of Medical Oncology, Luohe Central Hospital, Luohe First People's Hospital, No. 56 People's East Road, Luohe City, 462000, Henan Province, China
| | - Tianjiang Ma
- Department of Medical Oncology, Luohe Central Hospital, Luohe First People's Hospital, No. 56 People's East Road, Luohe City, 462000, Henan Province, China.
| |
Collapse
|